<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04986748</url>
  </required_header>
  <id_info>
    <org_study_id>Q-SAM</org_study_id>
    <nct_id>NCT04986748</nct_id>
  </id_info>
  <brief_title>Using QPOP to Predict Treatment for Sarcomas and Melanomas</brief_title>
  <official_title>Q-SAM (Using QPOP to Predict Treatment for Sarcomas and Melanomas)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Centre, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-cohort proof of concept study involving patients with sarcomas or melanomas.&#xD;
      Patient models, both two- and three-dimensional, will be derived from tumour samples. These&#xD;
      will then be used to evaluate drug sensitivities ex vivo.&#xD;
&#xD;
      Enrolled patients will undergo resections or biopsies as part of standard-of-care, which will&#xD;
      be used to generate patient models. Patients will receive standard-of-care systemic&#xD;
      treatment. Patient models will also be subjected up to a 14-drug screening panel. The&#xD;
      majority of drugs in the respective drug panels has been shown to have activity in the&#xD;
      respective cancers and would be used in the standard-of-care setting by treating physicians.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: Ex vivo drug testing on patient-derived models using QPOP can identify drug&#xD;
      sensitivities and combinations which may have clinical efficacy against sarcomas and&#xD;
      melanomas.&#xD;
&#xD;
      Specific aim 1: To derive patient models, both two- and three-dimensional, of sarcomas and&#xD;
      melanomas&#xD;
&#xD;
      Specific aim 2: To perform ex vivo drug testing on patient models of sarcoma and melanoma&#xD;
      using QPOP&#xD;
&#xD;
      Specific aim 3: To assess the efficacy of phenotype directed therapy using QPOP to assign&#xD;
      treatment after progression on standard-of-care treatment in sarcoma and melanoma&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with successful model generation for each tumour subtype.</measure>
    <time_frame>8 years.</time_frame>
    <description>Patients enrolled on study will undergo resection or biopsy of fresh tumour tissue to obtain cells for the generation of models.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rates of radiological response from QPOP-directed treatment regimens.</measure>
    <time_frame>8 years.</time_frame>
    <description>Complete and partial clinical response and stable disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival outcomes from QPOP-directed treatment regimens.</measure>
    <time_frame>8 years.</time_frame>
    <description>Overall survival, progression-free survival.</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Sarcoma</condition>
  <condition>Melanoma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumour Samples - Baseline upon study enrolment and on disease progression where clinically&#xD;
      applicable.&#xD;
&#xD;
      Enrolled patients undergoing a procedure where tumour tissue is removed for diagnostic or&#xD;
      other clinical purposes, will be asked to donate any tissue that is in excess and not needed&#xD;
      for diagnostic purposes, for this research study.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient aged between 21 to 99 diagnosed with sarcoma or melanoma.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of sarcoma or melanoma&#xD;
&#xD;
          -  At least 1 tumour lesion amenable to fresh biopsy or resection&#xD;
&#xD;
          -  Signed informed consent from patient or legal representative&#xD;
&#xD;
          -  Able to comply with study-related procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  There are no specific exclusion criteria if patients meet the inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valerie Shiwen Yang, BSc, MB BChir, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Centre, Singapore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valerie Shiwen Yang, BSc, MB BChir, PhD</last_name>
    <phone>+65 6436 8088</phone>
    <email>valerie.yang.s.w@singhealth.com.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Centre Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Shiwen Yang, BSc, MB BChir, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tumour-derived models</keyword>
  <keyword>Organoids</keyword>
  <keyword>Ex vivo drug testing</keyword>
  <keyword>Personalised therapy</keyword>
  <keyword>QPOP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

